人工授精市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、組件、來源、最終用戶、地區及競爭格局分類，2021-2031年）

全球人工授精市場預計將從 2025 年的 30.8 億美元成長到 2031 年的 46.6 億美元，複合年成長率為 7.15%。

人工授精是一種專門的輔助生殖技術，它利用儀器將精子注入雌性生殖道，無需自然交配即可實現受精。該市場的主要驅動力是農業領域加速遺傳改良的需求，它使生產者能夠比自然交配更有效地提高牲畜的生產力和性狀品質。此外，嚴格的生物安全措施也是推動該技術發展的重要因素，因為這種方法顯著降低了牲畜間性行為感染傳染病的風險。

同時，市場擴張的主要障礙包括對高技能技術人員的需求以及確保受孕成功率所需的高成本低溫運輸基礎設施。這些技術障礙往往會推高營運成本，並限制缺乏健全物流網路的發展中地區的供應。美國國家動物育種者協會 (NAAB) 的報告強調了該行業的最新趨勢，報告稱，美國牛精液行業到 2024 年的總銷售量將達到約 6900 萬份，比上一年成長 4%。

市場促進因素

男性和女性不孕症發病率的上升，尤其是在醫療保健領域，是推動全球人工授精市場擴張的主要因素。這一成長主要源於生活方式的改變和全球生育年齡延遲的趨勢，導致人們越來越需要醫療輔助才能懷孕。隨著自然受孕率因老齡化和環境因素而下降，人們對輔助生殖技術的依賴性日益增強，使得人工授精成為全球夫婦和非傳統家庭的重要服務。為了凸顯這項挑戰的嚴峻性，世界衛生組織（世衛組織）於2025年11月發布了一份「不孕症」情況說明書，估計全球約有六分之一的育齡人口在其一生中將面臨不孕不育的困擾，這凸顯了對有效生殖解決方案的巨大且不斷成長的需求。

畜牧業遺傳改良和疾病管理的需求是獸醫領域的第二大市場促進因素。生產者擴大採用人工授精來傳播優良的遺傳性狀，例如提高飼料轉換率和增強抗病能力，這對於滿足全球對優質動物蛋白日益成長的需求至關重要。這種做法也能降低自然繁殖帶來的生物安全風險，促進畜群健康發展，並實現永續的生產週期。為了佐證遺傳改良的商業性價值，Genus plc 在 2025 年 9 月發布的「截至 2025 年 6 月 30 日的年度初步業績報告」中指出，其牛隻部門的累計營業利潤為 1,950 萬英鎊。此外，Viking Genetics 在 2025 年 4 月發布的「2024 年年度報告」中也反映了更廣泛的市場趨勢，報告顯示，該合作社的總收入達到 3,510 萬歐元，主要得益於性別分選精液銷量的成長。

市場挑戰

對高技能技術人員和先進低溫運輸基礎設施的需求是全球人工授精市場成長的一大障礙。這項輔助生殖技術高度依賴透過持續低溫儲存和授精過程中的嚴格操作來維持胚胎的生物活性。物流流程中的任何疏忽或操作人員技能的不足都可能導致受孕率下降，從而大幅增加每次懷孕的成本，並降低生產者的投資報酬率。因此，在缺乏技術培訓和穩定能源基礎設施的地區，採用這項技術在經濟上仍然不切實際。

遺傳物質市場價值的上漲加劇了這個財務負擔，增加了營運所需的資金。不斷上漲的投入成本限制了小型企業和發展中市場的准入，因為它們無法負擔先進物流相關的高昂成本。根據美國國家畜牧育種者協會預測，受平均混合精液價格持續上漲的推動，美國精液出口額預計將在2024年成長超過6%，達到創紀錄的3.26億美元。成本上漲的趨勢直接阻礙了精液的普及，提高了市場進入的財務門檻。

市場趨勢

微流體技術在精子分選領域的應用正在革新臨床工作流程，取代了傳統的離心技術，後者常導致DNA碎片化。這些先進的設備模擬女性生殖道的天然屏障，分離出具有高活力、高存活率和優異基因組完整性的精子，從而提高人工授精的受孕率。這項技術革新正在推動產業整合，並促使領先的生育機構擴大產品組合。例如，Cooper Surgical在2024年6月發布的通訊協定中宣布收購ZyMot Fertility，並將其微流體精子分選設備納入其全球產品組合，該新聞稿題為“精子分離技術加入Cooper Surgical的核心生育產品和服務”，凸顯了其對先進分選解決方案的商業性關注。

同時，數位生育治療平台的激增和遠端醫療的整合，透過提供克服地理限制的虛擬醫療模式，正在重新定義市場准入。這些平台能夠實現遠距離診斷、週期追蹤以及為家庭人工授精和診所協調提供後勤支持，從而有效降低了準父母的准入門檻。這種醫療保健的去中心化趨勢正在吸引大量投資，以拓展虛擬診所的服務範圍。例如，數位醫療公司Maven Clinic在2024年10月的新聞稿「Maven Clinic宣布完成1.25億美元F輪資金籌措」中宣布，已籌集1.25億美元用於拓展其虛擬生育治療和家庭構建支援服務，這印證了市場對技術主導的遠距生育服務的日益依賴。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球人工授精市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術（子宮頸內、子宮頸內、陰道內、輸卵管內）
  • 依組件分類（人工授精套裝、家用人工授精裝置、其他）
  • 依來源（配偶人工受孕、捐精）
  • 依最終使用者（醫院、生育診所/中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美人工授精市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲人工授精市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區人工授精市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲人工授精市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲人工授精市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球人工授精市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Ocket Medical plc
• Kitazato Corporation
• Vitrolife AB
• Genea Limited
• Rinovum Women's Health, LLC
• Pride Angel Limited
• FUJIFILM Irvine Scientific, Inc.
• Conceivex, Inc.
• Surelife Pte Ltd.
• Biogenics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Artificial Insemination Market is projected to expand from a valuation of USD 3.08 Billion in 2025 to USD 4.66 Billion by 2031, reflecting a compound annual growth rate of 7.15%. Defined as a specialized assisted reproductive technology, artificial insemination involves the instrumental delivery of sperm into the female reproductive tract to achieve fertilization without natural mating. The market is predominantly underpinned by the agricultural sector's need for accelerated genetic enhancement, enabling producers to improve herd productivity and trait quality more effectively than natural service methods. Additionally, the stringent requirement for biosecurity measures serves as a key propellant, as this method substantially lowers the risk of transmitting venereal diseases among livestock.

Conversely, a major obstacle hindering widespread market growth is the necessity for highly proficient technicians and costly cold-chain infrastructure to guarantee successful conception rates. This technical hurdle frequently elevates operational expenses and restricts availability in developing areas lacking robust logistics. Highlighting the industry's recent trajectory, the National Association of Animal Breeders reported that in 2024, the U.S. bovine semen industry achieved a total sales volume of nearly 69 million units, marking a 4% rise compared to the prior year.

Market Driver

The rising incidence of male and female infertility serves as a primary driver for the expansion of the Global Artificial Insemination Market, particularly within the human healthcare sector. This growth is substantially fueled by lifestyle shifts and a global trend toward delayed parenthood, which increase the need for medical assistance to realize conception. As natural fertility rates diminish due to aging and environmental influences, dependence on assisted reproductive technologies has deepened, making artificial insemination a vital service for couples and non-traditional families globally. Emphasizing the magnitude of this challenge, the World Health Organization's 'Infertility' fact sheet from November 2025 estimates that roughly one in six individuals of reproductive age worldwide will face infertility during their lifetime, highlighting the critical and expanding demand for effective reproductive solutions.

The need for genetic advancement and disease control in livestock acts as a second major market propeller, driving the veterinary segment. Producers are increasingly utilizing artificial insemination to propagate superior genetic traits, such as improved feed efficiency and disease resistance, which are crucial for satisfying the growing global appetite for high-quality animal protein. This approach also mitigates biosecurity threats linked to natural mating, promoting healthier herds and sustainable production cycles. Validating the commercial significance of these genetic improvements, Genus plc's 'Preliminary Results for the Year Ended 30 June 2025' released in September 2025 noted that its bovine division generated an adjusted operating profit of £19.5 million. Furthermore, illustrating broader market trends, VikingGenetics reported in its '2024 Annual Report Announcement' from April 2025 that the cooperative achieved total revenue of EUR 35.1 million, largely fueled by increasing sales of sexed-sorted semen doses.

Market Challenge

The necessity for highly capable technicians and advanced cold-chain infrastructure poses a significant obstacle to the growth of the global artificial insemination market. This reproductive technology depends heavily on maintaining biological viability through continuous cryogenic storage and exacting handling during the insemination procedure. Any breakdown in this logistical sequence or deficiency in operator skill leads to lower conception rates, effectively raising the cost per pregnancy and eroding the return on investment for producers. Consequently, in areas where technical training and stable energy infrastructure are lacking, implementing this technology remains economically impractical.

This financial burden is further exacerbated by the increasing market value of genetic materials, which raises the capital needed for operations. Elevated input costs restrict access for smaller businesses and developing markets that are unable to afford the premiums linked to sophisticated logistics. According to the National Association of Animal Breeders, the value of U.S. semen exports grew by over 6% in 2024 to reach a record $326 million, driven by a sustained increase in the average blend price. This trend of rising costs directly inhibits widespread adoption by raising the financial barrier required to enter the market.

Market Trends

The integration of microfluidic technologies for sperm sorting is revolutionizing clinical workflows by superseding traditional centrifugation techniques that frequently induce DNA fragmentation. These advanced devices simulate the natural barriers of the female reproductive tract to isolate highly motile, viable sperm with superior genomic integrity, thereby improving fertilization rates in artificial insemination protocols. This technological evolution is fostering significant industry consolidation and portfolio broadening among leading fertility organizations. For instance, CooperSurgical announced in a June 2024 press release titled 'Sperm Separation Technology Adds to CooperSurgical's Leading Fertility Products and Services' that it acquired ZyMot Fertility to incorporate its microfluidic sperm separation devices into their global offerings, highlighting the commercial focus on advanced sorting solutions.

Simultaneously, the proliferation of digital fertility platforms and telehealth integration is redefining market access by providing virtual care models that overcome geographic constraints. These platforms facilitate remote diagnostics, cycle tracking, and logistical assistance for at-home insemination or clinic coordination, effectively reducing entry barriers for prospective parents. This decentralization of reproductive healthcare has drawn considerable investment capital dedicated to expanding virtual clinic frameworks. As evidence of this trend, the digital health company Maven Clinic stated in its October 2024 'Maven Clinic Announces $125 Million Series F Round of Funding' press release that it raised $125 million to broaden its virtual fertility and family-building benefits, confirming the increasing market dependence on technology-driven remote reproductive services.

Key Market Players

• Ocket Medical plc
• Kitazato Corporation
• Vitrolife AB
• Genea Limited
• Rinovum Women's Health, LLC
• Pride Angel Limited
• FUJIFILM Irvine Scientific, Inc.
• Conceivex, Inc.
• Surelife Pte Ltd.
• Biogenics Inc

Report Scope

In this report, the Global Artificial Insemination Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Insemination Market, By Technique

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

Artificial Insemination Market, By Component

• Insemination Kits
• Home Conception Devices
• Others

Artificial Insemination Market, By Source

• AIH-Husband
• AID-Donor

Artificial Insemination Market, By End User

• Hospitals
• Fertility Clinics & Centers
• Others

Artificial Insemination Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Insemination Market.

Available Customizations:

Global Artificial Insemination Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Artificial Insemination Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technique (Intrauterine, Intracervical, Intravaginal, Intratubal)
  • 5.2.2. By Component (Insemination Kits, Home Conception Devices, Others)
  • 5.2.3. By Source (AIH-Husband, AID-Donor)
  • 5.2.4. By End User (Hospitals, Fertility Clinics & Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Artificial Insemination Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technique
  • 6.2.2. By Component
  • 6.2.3. By Source
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Artificial Insemination Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technique
      • 6.3.1.2.2. By Component
      • 6.3.1.2.3. By Source
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Artificial Insemination Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technique
      • 6.3.2.2.2. By Component
      • 6.3.2.2.3. By Source
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Artificial Insemination Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technique
      • 6.3.3.2.2. By Component
      • 6.3.3.2.3. By Source
      • 6.3.3.2.4. By End User

7. Europe Artificial Insemination Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technique
  • 7.2.2. By Component
  • 7.2.3. By Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Artificial Insemination Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technique
      • 7.3.1.2.2. By Component
      • 7.3.1.2.3. By Source
      • 7.3.1.2.4. By End User
  • 7.3.2. France Artificial Insemination Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technique
      • 7.3.2.2.2. By Component
      • 7.3.2.2.3. By Source
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Artificial Insemination Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technique
      • 7.3.3.2.2. By Component
      • 7.3.3.2.3. By Source
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Artificial Insemination Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technique
      • 7.3.4.2.2. By Component
      • 7.3.4.2.3. By Source
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Artificial Insemination Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technique
      • 7.3.5.2.2. By Component
      • 7.3.5.2.3. By Source
      • 7.3.5.2.4. By End User

8. Asia Pacific Artificial Insemination Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technique
  • 8.2.2. By Component
  • 8.2.3. By Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Artificial Insemination Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technique
      • 8.3.1.2.2. By Component
      • 8.3.1.2.3. By Source
      • 8.3.1.2.4. By End User
  • 8.3.2. India Artificial Insemination Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technique
      • 8.3.2.2.2. By Component
      • 8.3.2.2.3. By Source
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Artificial Insemination Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technique
      • 8.3.3.2.2. By Component
      • 8.3.3.2.3. By Source
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Artificial Insemination Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technique
      • 8.3.4.2.2. By Component
      • 8.3.4.2.3. By Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Artificial Insemination Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technique
      • 8.3.5.2.2. By Component
      • 8.3.5.2.3. By Source
      • 8.3.5.2.4. By End User

9. Middle East & Africa Artificial Insemination Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technique
  • 9.2.2. By Component
  • 9.2.3. By Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Artificial Insemination Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technique
      • 9.3.1.2.2. By Component
      • 9.3.1.2.3. By Source
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Artificial Insemination Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technique
      • 9.3.2.2.2. By Component
      • 9.3.2.2.3. By Source
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Artificial Insemination Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technique
      • 9.3.3.2.2. By Component
      • 9.3.3.2.3. By Source
      • 9.3.3.2.4. By End User

10. South America Artificial Insemination Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technique
  • 10.2.2. By Component
  • 10.2.3. By Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Artificial Insemination Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technique
      • 10.3.1.2.2. By Component
      • 10.3.1.2.3. By Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Artificial Insemination Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technique
      • 10.3.2.2.2. By Component
      • 10.3.2.2.3. By Source
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Artificial Insemination Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technique
      • 10.3.3.2.2. By Component
      • 10.3.3.2.3. By Source
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Artificial Insemination Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ocket Medical plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Kitazato Corporation
• 15.3. Vitrolife AB
• 15.4. Genea Limited
• 15.5. Rinovum Women's Health, LLC
• 15.6. Pride Angel Limited
• 15.7. FUJIFILM Irvine Scientific, Inc.
• 15.8. Conceivex, Inc.
• 15.9. Surelife Pte Ltd.
• 15.10. Biogenics Inc

16. Strategic Recommendations

17. About Us & Disclaimer